Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
26 hedge funds and large institutions have $15M invested in Zynerba Pharmaceuticals, Inc in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 13 closing their positions.
13% less funds holding
Funds holding: 30 → 26 (-4)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
42% less capital invested
Capital invested by funds: $26M → $15M (-$11M)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
+$478K |
| 2 |
AGM
Alpine Global Management
New York
|
+$138K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$137K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$107K |
| 5 |
Bank of New York Mellon
New York
|
+$84.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.12M |
| 2 |
JP Morgan Chase
New York
|
-$1.65M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$613K |
| 4 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$468K |
| 5 |
State Street
Boston,
Massachusetts
|
-$356K |
ZYNE Hedge Fund Activity: Q2 2016 in Review
26 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q2 2016, worth a combined $15M — down 42% from $26M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ZYNE and 9 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 5 added.
The largest buyer was Nexthera Capital, opening a new position worth an estimated $478K. The largest seller was RA Capital Management, cutting an estimated $2.12M.
- 26 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q2 2016, down from 30 in Q1 2016.
- Funds reported $15M of Zynerba Pharmaceuticals, Inc stock for Q2 2016, down 42% quarter-over-quarter.
- 9 funds opened new Zynerba Pharmaceuticals, Inc positions in Q2 2016 and 13 closed out, a net change of -4 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q2 2016 was Nexthera Capital, an estimated $478K added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q2 2016 was RA Capital Management, an estimated $2.12M sold.
Based on aggregated 13F filings for Q2 2016.